Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Non-Current Deffered Revenue (2016 - 2018)

Altimmune (ALT) has disclosed Non-Current Deffered Revenue for 5 consecutive years, with $1.0 million as the latest value for Q4 2018.

  • On a quarterly basis, Non-Current Deffered Revenue rose 170.59% to $1.0 million in Q4 2018 year-over-year; TTM through Dec 2018 was $1.0 million, a 170.59% increase, with the full-year FY2018 number at $1.0 million, up 170.59% from a year prior.
  • Non-Current Deffered Revenue was $1.0 million for Q4 2018 at Altimmune, down from $1.1 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $1.1 million in Q3 2018 to a low of $1591.0 in Q3 2017.
  • A 3-year average of $376757.2 and a median of $162140.0 in 2017 define the central range for Non-Current Deffered Revenue.
  • Biggest YoY gain for Non-Current Deffered Revenue was 68422.44% in 2018; the steepest drop was 11.66% in 2018.
  • Altimmune's Non-Current Deffered Revenue stood at $15914.0 in 2016, then skyrocketed by 2328.61% to $386489.0 in 2017, then soared by 170.59% to $1.0 million in 2018.
  • Per Business Quant, the three most recent readings for ALT's Non-Current Deffered Revenue are $1.0 million (Q4 2018), $1.1 million (Q3 2018), and $149785.0 (Q2 2018).